An estimated $216M Q3 expense lowers AbbVie (ABBV)'s 2026 adjusted earnings outlook.
An estimated $216M Q3 expense lowers AbbVie (ABBV)'s 2026 adjusted earnings outlook. Stock Titan
Covered in this story
Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Guggenheim: $244 → $288 by Aug 2027 · Buy via GuruFocus
- Canaccord Genuity: $245 → $290 by Aug 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 49 stories mentioning AbbVie, the earliest published 11 Jun 2026.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.